The development of drugs to treat major diseases of the central nervous system relies in part on the development of novel strategies to cross the blood brain barrier. Michel Khrestchatisky and ...
While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...
Medical Xpress on MSN13d
Breakthrough study led by CHLA neurologists links blood-brain barrier dysfunction and inflammation with Down syndrome regression disorderSantoro, MD, Director of the Neuroimmunology Program at Children’s Hospital Los Angeles, shows evidence of dysfunction of the ...
"In contrast, very few neurons in the central nervous system itself expressed Cdkl ... Borja, Stephanie Bivona, Undiagnosed Diseases Network, Baylor College of Medicine Center for Precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback